Hyperfine Launches Study to Expand Swoop MRI System with Contrast Agents

Event summary

  • Hyperfine enrolled the first patient in the Contrast PMR study to evaluate contrast-enhanced ultra-low-field portable MRI.
  • The study aims to support a future FDA submission to expand the Swoop® system’s intended use to include gadolinium-based contrast agents.
  • The study will enroll approximately 70 patients across multiple sites in the United States.
  • Hyperfine anticipates submission to the FDA for indication expansion towards the end of 2026.

The big picture

Hyperfine's study represents a strategic move to enhance the clinical utility of its portable MRI system, potentially unlocking new applications in brain imaging. This aligns with broader industry trends towards more accessible and versatile diagnostic tools, particularly in neurological conditions. The success of this study could position Hyperfine as a leader in portable medical imaging technology.

What we're watching

Regulatory Approval
Whether the FDA will approve the expanded use of the Swoop® system with contrast agents by the end of 2026.
Market Expansion
How the addition of contrast agents will affect the adoption of the Swoop® system in new clinical settings.
Competitive Dynamics
The pace at which Hyperfine can differentiate itself from traditional MRI systems with this enhancement.